Fate Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Fate Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Fate Therapeutics, Inc.
The story matters when it changes Fate Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call Transcript
Investors are testing whether Fate Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE
The story matters when it changes Fate Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)
Investors are testing whether Fate Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.As Fate Therapeutics, Inc.'s (NASDAQ:FATE)) market cap dropped by US$104m, insiders who sold US$4.2m worth of stock were able to offset their losses
Investors are testing whether Fate Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Insiders of Fate Therapeutics, Inc. (NASDAQ:FATE) would have made a tidy sum after selling US$12m worth of stock at a high price
Investors are testing whether Fate Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest FATE filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Fate Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →